https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Aridis_Pharmaceuticals%2C_Inc.Aridis Pharmaceuticals, Inc. - Revizia istoricului2026-04-18T13:50:09ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Aridis_Pharmaceuticals,_Inc.&diff=407073&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Aridis Pharmaceuticals, Inc. listata cu simbolul US.ARDS ==Descriere companie== Aridis Pharmaceuticals, Inc. (www.aridispharma.com) is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associ...2024-09-18T13:38:45Z<p>Pagină nouă: Pagina dedicata companiei Aridis Pharmaceuticals, Inc. listata cu simbolul US.ARDS ==Descriere companie== Aridis Pharmaceuticals, Inc. (www.aridispharma.com) is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associ...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Aridis Pharmaceuticals, Inc. listata cu simbolul US.ARDS<br />
<br />
==Descriere companie==<br />
Aridis Pharmaceuticals, Inc. (www.aridispharma.com) is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ARDS" /><br />
<br />
==Ultimele stiri despre Aridis Pharmaceuticals, Inc. (US.ARDS)==<br />
<dynamicpagelist><br />
category=US.ARDS<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ARDS]][[Categorie:Stiri despre companii]]</div>Admin